|Bid||15.46 x 2200|
|Ask||15.57 x 1800|
|Day's Range||14.95 - 15.63|
|52 Week Range||3.85 - 33.95|
|Beta (5Y Monthly)||-2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.33|
Humanigen announces positive results from the Phase 1 safety and bioimaging trial of ifabotuzumab.
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Humanigen announced it completed its underwritten public offering of common stock.